Quick Takeaways: Why It Matters? Boehringer Ingelheim’s purchase of Evax gives it a promising new way to treat common horse allergies with longer‑lasting vaccines instead of short‑term symptom relief, which could mean fewer vet visits and better outcomes for owners. If the approach works a...
Quick Takeaways: Why It Matters? Boehringer Ingelheim and Eko are turning every canine auscultation into a structured, AI‑backed cardiac assessment, using Eko Vet+ | CANINEBEAT AI to detect and grade heart murmurs with over 95% sensitivity and specificity against murmurs linked...
Quick Takeaways: Why It Matters? Lenzelta gives Boehringer Ingelheim a next‑generation mastitis vaccine that fits neatly into dry‑off protocols: two intramuscular doses in late gestation deliver early‑onset immunity and up to six months...
Quick Takeaways: Why It Matters? The EUAs immediately expand the therapeutic toolkit for a serious, fast-moving parasitic threat, positioning NexGard and NexGard COMBO as go‑to options if New World screwworm spreads beyond current foci in northern Mexico.&nb...
Quick Takeaways: Why It Matters? The EUA gives producers and vets a vetted, over‑the‑counter preventive option at key intervention points (birth, castration, wounds), strengthening biosecurity plans if New World screwworm encroaches toward US herds. Fo...
Quick Takeaways: Why It Matters? Full approval and label expansion make Vetmedin the standard of care for early-stage MMVD, locking in pimobendan as the only FDA‑approved option for delaying CHF in Stage B2 dogs and driving guideline‑aligned, earli...
Revenue: $5.4M Founded Year: 1982 Market Cap: 54.85M Total Employees: ~70 Headquarters: Maine, United States Stock Exchange: NASDAQ ImmuCell is an animal health company that aims towards the development, manufacturing, and marketing of scientifically-proven products that improve health and...
